Plant ID: NPO29314
Plant Latin Name: Mangifera indica
Taxonomy Genus: Mangifera
Taxonomy Family: Anacardiaceae
NCBI TaxonomyDB:
29780
Plant-of-the-World-Online:
69913-1
Brazil; Bangladesh; Sudan; Guinea; Costa Rica; Cambodia; Bahamas; Somalia; Peru; Swaziland; Argentina; Cameroon; Burkina Faso; Ecuador; Ghana; Cuba; El Salvador; Venezuela; Zambia; Malawi; Togo; Zimbabwe; China; Dominican Republic; Belize; Tanzania; Nigeria; Netherlands; Gambia; Philippines; New Caledonia; Mauritius; Trinidad and Tobago; Gabon; Guinea-Bissau; Honduras; Haiti; Jamaica; Angola; Myanmar; Mexico; South Africa; India; Malaysia; Senegal; Congo; Mozambique; Sri Lanka; Kenya; Fiji
FFAR1; FFAR4; GPR35; | |
NPSR1; | |
RECQL; TDP1; ALPL; HPGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; ALOX15; NOX4; APEX1; POLB; | |
ACHE; | |
BCL2; | |
TRPV1; | |
LCK; TEK; KDR; LIMK1; PIM1; MET; INSR; AXL; FLT3; CDK1; EGFR; CDK6; SRC; IGF1R; PRKCA; AURKB; NUAK1; CSNK2A1; | |
POLA1; FUT7; | |
CA2; CA12; CA14; CA7; CA1; | |
PPARA; | |
NR1H4; | |
TYR; | |
KDM4E; | |
F10; | |
AHR; NFKB1; | |
SLC22A6; SLCO1B1; | |
LMNA; FABP3; FABP5; SMAD3; FABP4; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | LIMK1 | LIM domain kinase 1 | P53667 | CHEMBL3836 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Transferase | POLA1 | DNA polymerase alpha subunit | P09884 | CHEMBL1828 |
Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.465E-10 | 3.072E-07 | CA1, CA12, CA14, CA2, CA7 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.296E-09 | 4.480E-07 | AXL, EGFR, F10, INSR, LCK, MET, NOX4, SRC, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.710E-09 | 7.973E-07 | AURKB, AXL, CDK1, CDK6, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, LCK, LIMK1, MET, NUAK1, PIM1, PRKCA, RECQL, SRC, TEK, TRPV1 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.269E-09 | 2.279E-06 | EGFR, IGF1R, INSR, KDR, LCK, SRC |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.310E-08 | 1.968E-05 | AKR1B1, ALOX12, BCL2, CDK1, CDK6, CSNK2A1, EGFR, FLT3, HPGD, IGF1R, INSR, KDR, PIM1, PRKCA, TEK |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.605E-07 | 3.013E-05 | ALPL, APEX1, CYP1A1, CYP1B1, EGFR, FLT3, NFKB1, NOX4, SRC, TRPV1 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.143E-07 | 3.763E-05 | ALOX15, EGFR, FFAR4, KDR, NOX4, PRKCA, SRC, TEK |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.851E-07 | 4.926E-05 | CA1, CA12, CA14, CA2, CA7 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.245E-07 | 5.435E-05 | BCL2, CA2, CA7, KDR, LCK, NPSR1, SRC, TRPV1 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.498E-06 | 1.964E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.598E-06 | 2.046E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.696E-06 | 2.160E-04 | BCL2, CYP1A1, LMNA, NOX4, PPARA, SMAD3, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.830E-06 | 2.316E-04 | FFAR4, NFKB1, NR1H4, PPARA, SMAD3, TEK |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.152E-06 | 2.647E-04 | AXL, IGF1R, INSR, LCK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.609E-06 | 3.105E-04 | EGFR, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.719E-06 | 4.153E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.343E-06 | 4.776E-04 | AKR1B1, ALOX12, ALOX15, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.482E-06 | 4.905E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
MF | Unclassified; | GO:0004872; receptor activity | 5.149E-06 | 5.524E-04 | AHR, AXL, EGFR, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, TEK, TRPV1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.247E-06 | 5.601E-04 | CA1, CA12, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 8.914E-06 | 8.986E-04 | EGFR, INSR, SMAD3, TRPV1 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.014E-05 | 9.767E-04 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.014E-05 | 9.767E-04 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.014E-05 | 9.767E-04 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.243E-05 | 1.171E-03 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, LCK, PIM1, PPARA, SMAD3, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.299E-05 | 1.209E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.316E-05 | 1.215E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.336E-05 | 1.227E-03 | AURKB, CDK1, CDK6, CSNK2A1, EGFR, LIMK1, NUAK1, PIM1, PRKCA |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.712E-05 | 1.534E-03 | ALOX12, ALOX15, HPGD |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.074E-05 | 1.810E-03 | AURKB, CDK1, PRKCA |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.889E-05 | 2.439E-03 | CA2, EGFR, HPGD, SLC22A6, SLCO1B1, TEK |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 2.903E-05 | 2.440E-03 | CDK1, EGFR, IGF1R, INSR |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.035E-05 | 2.457E-03 | CA2, CA7 |
BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 3.035E-05 | 2.457E-03 | BCL2, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.035E-05 | 2.457E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.035E-05 | 2.457E-03 | ALOX12, ALOX15 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 3.120E-05 | 2.517E-03 | AHR, AKR1B1, APEX1, AURKB, BCL2, CDK1, CDK6, CSNK2A1, FABP5, HPGD, HSPA1A, LMNA, NFKB1, NR1H4, NUAK1, PIM1, POLA1, POLB, PPARA, PRKCA, RECQL, SMAD3, SRC |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 3.244E-05 | 2.588E-03 | ALOX15, ALPL, BCL2, EGFR, TEK |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.399E-05 | 2.662E-03 | AHR, AXL, BCL2, CSNK2A1, EGFR, PPARA, SRC |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 3.837E-05 | 2.963E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
MF | Unclassified; | GO:0032403; protein complex binding | 3.991E-05 | 3.071E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, LCK, PPARA, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.019E-05 | 3.082E-03 | CYP1A1, CYP1A2, CYP1B1 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 4.144E-05 | 3.133E-03 | EGFR, INSR, KDR, LCK, SLC22A6, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.327E-05 | 3.906E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.327E-05 | 3.906E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 5.397E-05 | 3.944E-03 | AKR1B1, APEX1, IGF1R, INSR, NFKB1, SRC |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.649E-05 | 4.114E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.057E-05 | 4.342E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 6.082E-05 | 4.342E-03 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.887E-05 | 4.788E-03 | FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 9.742E-05 | 6.488E-03 | AURKB, CDK1, PRKCA |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 9.876E-05 | 6.556E-03 | APEX1, CDK1, CYP1A1, INSR, PRKCA |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.007E-04 | 6.607E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 1.088E-04 | 6.950E-03 | ACHE, HSD17B10, IGF1R, INSR, TRPV1 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.093E-04 | 6.957E-03 | ALOX15, EGFR, PPARA, SMAD3 |
BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 1.114E-04 | 7.070E-03 | APEX1, EGFR, FFAR4, FLT3, INSR, NFKB1, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.149E-04 | 7.231E-03 | BCL2, CDK1, CSNK2A1, PRKCA |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.188E-04 | 7.456E-03 | AXL, FFAR1, FFAR4, FLT3, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, SLCO1B1, TEK, TRPV1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.202E-04 | 7.499E-03 | FLT3, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.268E-04 | 7.865E-03 | FABP3, FFAR1, NR1H4, SRC |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.354E-04 | 8.283E-03 | ALOX12, CYP1B1, KDR, PRKCA, TEK |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.390E-04 | 8.397E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, HSD17B2, NR1H4 |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.395E-04 | 8.397E-03 | ALPL, CYP1A1, EGFR, TYR |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.462E-04 | 8.696E-03 | AHR, CSNK2A1, KDR |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.508E-04 | 8.875E-03 | CA1, CA2 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.524E-04 | 8.939E-03 | ACHE, BCL2, CSNK2A1, EGFR, FLT3, HPGD, IGF1R, KDR, LCK, MET, NFKB1, SLC22A6, SMAD3, TRPV1, TYR |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.604E-04 | 9.240E-03 | INSR, PPARA, SRC |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.604E-04 | 9.240E-03 | ACHE, EGFR, IGF1R, INSR |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.620E-04 | 9.305E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:2000045; regulation of G1/S transition of mitotic cell cycle | 1.716E-04 | 9.707E-03 | APEX1, BCL2, CDK1, CYP1A1, EGFR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.968E-09 | 2.627E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.914E-08 | 3.945E-06 | CDK6, INSR, KDR, BCL2, PRKCA, TEK, MET, EGFR, NFKB1, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.460E-09 | 2.584E-07 | CA12, CA1, CA2, CA7, CA14 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.047E-08 | 1.798E-06 | INSR, BCL2, PRKCA, TEK, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.787E-07 | 9.866E-06 | SRC, INSR, KDR, PRKCA, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 4.858E-07 | 1.228E-05 | INSR, KDR, PRKCA, TEK, MET, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.622E-07 | 1.228E-05 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.500E-06 | 6.425E-05 | CDK6, SMAD3, FLT3, BCL2, PRKCA, MET, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.969E-06 | 6.425E-05 | SRC, KDR, BCL2, PRKCA, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.630E-06 | 6.425E-05 | CDK6, PIM1, BCL2, CYP1B1, PRKCA, MET, EGFR, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.994E-06 | 9.645E-05 | SMAD3, CDK6, SRC, BCL2, PRKCA, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.531E-05 | 2.084E-04 | SMAD3, PIM1, BCL2, PRKCA, NFKB1 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.509E-05 | 2.084E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.890E-05 | 4.590E-04 | SRC, KDR, PRKCA, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.919E-05 | 5.440E-04 | CDK6, PRKCA, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.225E-05 | 5.440E-04 | CDK6, SMAD3, EGFR, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.133E-05 | 3.961E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.876E-05 | 5.778E-04 | SRC, MET, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 6.963E-05 | 6.162E-04 | CDK6, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.678E-04 | 1.350E-03 | BCL2, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.432E-04 | 1.722E-03 | SRC, PRKCA, ALOX12, TRPV1 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.224E-05 | 5.798E-04 | FABP3, FABP4, FABP5, PPARA |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.607E-04 | 1.350E-03 | SRC, CDK1, PRKCA, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 4.057E-04 | 2.660E-03 | CSNK2A1, BCL2, CDK1, NFKB1, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.386E-04 | 1.722E-03 | HPGD, FLT3, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.340E-04 | 2.743E-03 | POLB, CDK6, SRC, CDK1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.988E-04 | 1.530E-03 | CSNK2A1, LCK, BCL2, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 7.736E-04 | 4.417E-03 | SMAD3, INSR, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 8.408E-04 | 4.651E-03 | CDK6, CSNK2A1, NFKB1, HSPA1A |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.352E-03 | 6.646E-03 | POLA1, FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, AKR1B1, ALPL, ALOX12, TYR, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 6.995E-04 | 4.269E-03 | CDK6, PRKCA, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.368E-04 | 4.347E-03 | FLT3, PIM1, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 8.983E-04 | 4.818E-03 | SRC, KDR, PRKCA |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.033E-03 | 5.378E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.180E-03 | 5.967E-03 | FLT3, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.512E-03 | 6.862E-03 | CDK6, SMAD3, NFKB1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.583E-04 | 1.758E-03 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.395E-03 | 6.676E-03 | SLCO1B1, CA2, NR1H4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.512E-03 | 6.862E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.111E-03 | 9.339E-03 | CYP1A2, CYP1A1, CYP1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
NA: NA | Christmas disease | NA | F10; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; FFAR1; |
NA: NA | Haemophilia B | NA | F10; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; TRPV1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; FFAR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | HIV infections | NA | AHR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
NA: NA | Edema | NA | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | TRPV1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; FFAR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; CA1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
A00-B99: Certain infectious and parasitic diseases | Viral infections | B01, B02, A60, B00, B27, G05.1, P35.2 | POLA1; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; BCL2; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1; |
NA: NA | Esophagus sensitivity | NA | TRPV1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; TEK; EGFR; SRC; CA1; BCL2; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; BCL2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |